Synapse - Lymphoma

Results (2708)

Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDAC™ degrader, in patients with non-Hodgkin's lymphoma

Meeting Abstract

Horwitz, S.; Jain, S.; Soumerai, J. D.; Tees, M. T.; Stuver, R.; Ali, A.; Leahy, L.; Lobbardi, R.; Chu, R.; Hurh, E.; more...
Blood (2024)

Fulltext@MSK | Save

Development of a novel prognostic score for relapsed/refractory mature T-cell and NK-cell lymphomas (PIRT): Results from a global peripheral T-cell lymphoma (PETAL) Consortium

Meeting Abstract

Koh, M. J.; Han, J. X.; Boussi, L.; Sorial, M. N.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J. J.; more...
Blood (2024)

Fulltext@MSK | Save

Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
Blood (2024)

Fulltext@MSK | Save

Integrating genomic & transcriptomic features for noninvasive detection, characterization, and monitoring of T-cell lymphomas

Meeting Abstract

Sugio, T.; Nesselbush, M.; Shukla, N.; Garofalo, A.; Mutter, J. A.; Esfahani, M. S.; Alig, S. K.; Shi, S.; Noordenbos, T.; Hamilton, M. P.; more...
Blood (2024)

Fulltext@MSK | Save

Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma

Meeting Abstract

Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
Blood (2024)

Fulltext@MSK | Save

Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial

Meeting Abstract

Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
Blood (2024)

Fulltext@MSK | Save

Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study

Meeting Abstract

Shadman, M.; Bartlett, N. L.; Matasar, M.; Schuster, S. J.; Assouline, S. E.; Sehn, L. H.; Kuruvilla, J.; Giri, P.; Cheah, C. Y.; Dietrich, S.; more...
Blood (2024)

Fulltext@MSK | Save

Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): TRANSCEND FL 2-year follow-up

Meeting Abstract

Nastoupil, L.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
Blood (2024)

Fulltext@MSK | Save

Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma

Meeting Abstract

Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
Blood (2024)

Fulltext@MSK | Save

Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis

Meeting Abstract

Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
Blood (2024)

Fulltext@MSK | Save